WHO ICTRP trial
Effect of spleen aminopeptide oral solution combined with Entecavir on…
ChiCTR2300073098 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2300073098 |
|---|---|
| Public title | Effect of spleen aminopeptide oral solution combined with Entecavir on HBeAg-positive chronic hepatitis B virus infection |
| Scientific title | Effect of spleen aminopeptide oral solution combined with Entecavir on HBeAg-positive chronic hepatitis B virus infection |
| Primary sponsor | The First Affiliated Hospital of China Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Chronic hepatitis B |
| Interventions | Control group:Entecaciv Dispersible Tablets;Test group:Spleen Aminopeptide Oral Solution + Entecaciv Dispersible Tablets |
| Registration date | Jun 30, 2023 |
| Target size | Control group:30;Test group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: